Correspondence 0001213900-24-061343 from Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp
Date: July 15, 2024 · CIK: 0002022416 · Accession: 0001213900-24-061343
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279281
Letter
VIA EDGAR Division of Corporation Finance Office of Finance Attention: Franklin Wyman Tim Buchmiller Re: Biomotion Sciences Registration Statement on Form S-4 SEC File Number 333-279281
Dear Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Biomotion Sciences hereby requests that the effective date of the above-referenced Registration Statement on Form S-4 be accelerated so that it will become effective at 4:30 p.m. Eastern time on July 16, 2024, or as soon as practicable thereafter.
Please contact Brian N. Wheaton, Esq., at Greenberg Traurig, LLP, our U.S. legal counsel, at (212) 801-6914 or wheatonb@gtlaw.com, or Jonathan M. Nathan, Adv., at Meitar Law Offices, our Israeli legal counsel, at +972-52-312-5574 or jonathann@meitar.com, with any questions, and please notify them when this request for acceleration has been granted.
Sincerely,
/s/ Ilan Levin
Show Raw Text
CORRESP
1
filename1.htm
Biomotion Sciences
250 Park Avenue, 7th Floor
New York, NY 10177
Telephone: (212) 572-6395
July 15, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Finance
100 F Street, NE
Washington, DC 20549
Attention:
Franklin Wyman
Kevin Vaughn
Daniel Crawford
Tim Buchmiller
Re:
Biomotion Sciences
Registration Statement on Form S-4
SEC File Number 333-279281
Dear Gentlemen:
Pursuant to Rule 461 under the Securities Act of
1933, as amended, Biomotion Sciences hereby requests that the effective date of the above-referenced Registration Statement on Form S-4
be accelerated so that it will become effective at 4:30 p.m. Eastern time on July 16, 2024, or as soon as practicable thereafter.
Please contact Brian N. Wheaton, Esq., at Greenberg
Traurig, LLP, our U.S. legal counsel, at (212) 801-6914 or wheatonb@gtlaw.com, or Jonathan M. Nathan, Adv., at Meitar Law Offices, our
Israeli legal counsel, at +972-52-312-5574 or jonathann@meitar.com, with any questions, and please notify them when this request for acceleration
has been granted.
Sincerely,
/s/ Ilan Levin
Ilan Levin
Chief Executive Officer
CC:
Gil Maman
Biomotion Sciences
Mark S. Selinger, Esq.
Brian N. Wheaton, Esq.
Gary Emmanuel, Esq.
Greenberg Traurig, LLP
J. David Chertok, Adv.
Jonathan M. Nathan, Adv.
Elad Ziv, Adv.
Meitar Law Offices